Evidence map›Paper›PMID 30282752›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2018

VASP Regulates NK Cell Lytic Granule Convergence.

Katelynn M Wilton, Daniel D Billadeau

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Katelynn M WiltonDepartment of Immunology, College of Medicine, Mayo Clinic, Rochester, MN 55905.ORCID 0000-0001-5060-8899
Daniel D BilladeauDepartment of Immunology, College of Medicine, Mayo Clinic, Rochester, MN 55905; billadeau.daniel@mayo.edu.ORCID 0000-0002-2296-9547
Mayo Clinic · US

Funding

Medical Scientist Traning Program at Mayo ClinicT32GM065841 · NIGMS · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, SCHIMMENTI, LISA A · 2003 to 2022
$5.8M
Mechanisms Regulating Human NK Cell CytotoxicityR01AI120949 · NIAID · MAYO CLINIC ROCHESTER · PI BILLADEAU, DANIEL D · 2016 to 2020
$2.0M
NIAID NIH HHS R01 AI120949NIGMS NIH HHS T32 GM065841
6 · The paper itself

Abstract

NK cells eliminate viral-infected and malignant cells through a highly orchestrated series of cytoskeletal rearrangements, resulting in the release of cytolytic granule contents toward the target cell. Central to this process is the convergence of cytolytic granules to a common point, the microtubule-organizing center (MTOC), before delivery to the synapse. In this study, we show that vasodialator-stimulated phosphoprotein (VASP), an actin regulatory protein, localizes to the cytolytic synapse, but surprisingly, shows no impact on conjugate formation or synaptic actin accumulation despite being required for human NK cell-mediated killing. Interestingly, we also find that a pool of VASP copurifies with lytic granules and localizes with lytic granules at the MTOC. Significantly, depletion of VASP decreased lytic granule convergence without impacting MTOC polarization. Using the KHYG-1 cell line in which lytic granules are in a constitutively converged state, we find that either VASP depletion or F-actin destabilization promoted spreading of formerly converged granules. Our results demonstrate a novel requirement for VASP and actin polymerization in maintaining lytic granule convergence during NK cell-mediated killing.

Indexed as

Actin CytoskeletonCell Adhesion MoleculesCytoplasmic GranulesCytotoxicity, ImmunologicHumansKiller Cells, NaturalLymphocyte ActivationMicrofilament ProteinsMicrotubule-Organizing CenterPhosphoproteinsVasodilator-Stimulated PhosphoproteinCell Adhesion MoleculesMicrofilament ProteinsPhosphoproteinsVasodilator-Stimulated Phosphoprotein

Identifiers

PMID30282752
PMCPMC6317751
OpenAlexW2894906139

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.